Certified by Founder Lodge
ARCH Venture Partners
United States - Chicago, IL
INVESTOR
1 Disclosed Funding Rounds $261,000,000
92 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Early stage venture firm focused on life science discoveries to prevent, detect and cure disease.
Date | Round | Raised | Participating Investors |
---|---|---|---|
September, 04 ,2024 | Series C | Undisclosed Amount |
Company | Date | Round | Raised |
---|---|---|---|
Magnet Biomedicine | September, 20 ,2023 | Unknown | $50,000,000 |
Colossal Biosciences | March, 09 ,2022 | Series A | $60,000,000 |
Treeline Biosciences | October, 18 ,2022 | Series A | $261,000,000 |
Boundless Bio | May, 17 ,2023 | Series C | $100,000,000 |
Orbital Therapeutics | April, 27 ,2023 | Series A | $270,000,000 |
AIRNA | September, 20 ,2023 | Unknown | $30,000,000 |
Neumora | October, 17 ,2022 | Series B | $112,000,000 |
OncoResponse | May, 19 ,2023 | Unknown | $14,000,000 |
Boundless Bio | May, 17 ,2023 | Series C | $100,000,000 |
Gate Bioscience | November, 02 ,2023 | Series A | $60,000,000 |
Happy Health | August, 24 ,2022 | Series A | $60,000,000 |
Myeloid Therapeutics | May, 19 ,2023 | Unknown | $73,000,000 |
Homeward | August, 03 ,2022 | Series B | $50,000,000 |
Tome Biosciences | December, 14 ,2023 | Series B | $213,000,000 |
OncoResponse | May, 19 ,2023 | Unknown | $14,000,000 |
Mozart Therapeutics, Inc | June, 08 ,2023 | Series A | $25,000,000 |
Paradigm | January, 30 ,2023 | Series A | $200,000,000 |
Remix Therapeutics | January, 04 ,2024 | Unknown | $60,000,000 |
Myeloid Therapeutics | May, 19 ,2023 | Unknown | $73,000,000 |
Rapport Therapeutics | March, 08 ,2023 | Series A | $100,000,000 |
Lightcast Discovery | August, 18 ,2023 | Series B | $49,000,000 |
Mozart Therapeutics, Inc | June, 08 ,2023 | Series A | $25,000,000 |
HI-Bio | January, 05 ,2024 | Series B | $95,000,000 |
Volastra Therapeutics | March, 08 ,2023 | Series A | $60,000,000 |
Generate:Biomedicines | September, 18 ,2023 | Series C | $273,000,000 |
Lightcast Discovery | August, 18 ,2023 | Series B | $49,000,000 |
Moonwalk Biosciences | January, 08 ,2024 | Series A | $57,000,000 |
Colossal Biosciences | March, 09 ,2022 | Series A | $60,000,000 |
Magnet Biomedicine | September, 20 ,2023 | Unknown | $50,000,000 |
Generate:Biomedicines | September, 18 ,2023 | Series C | $273,000,000 |
Elephas | January, 24 ,2024 | Series C | $55,000,000 |
Orbital Therapeutics | April, 27 ,2023 | Series A | $270,000,000 |
AIRNA | September, 20 ,2023 | Unknown | $30,000,000 |
Magnet Biomedicine | September, 20 ,2023 | Unknown | $50,000,000 |
Boundless Bio | May, 17 ,2023 | Series C | $100,000,000 |
Accompany Health | February, 01 ,2024 | Series A | $56,000,000 |
AIRNA | September, 20 ,2023 | Unknown | $30,000,000 |
Gate Bioscience | November, 02 ,2023 | Series A | $60,000,000 |
OncoResponse | May, 19 ,2023 | Unknown | $14,000,000 |
Basking Biosciences Inc | February, 02 ,2024 | Unknown | $55,000,000 |
Gate Bioscience | November, 02 ,2023 | Series A | $60,000,000 |
Tome Biosciences | December, 14 ,2023 | Series B | $213,000,000 |
Myeloid Therapeutics | May, 19 ,2023 | Unknown | $73,000,000 |
Proniras Corporation | February, 02 ,2024 | Series B | $4,650,000 |
Tome Biosciences | December, 14 ,2023 | Series B | $213,000,000 |
Remix Therapeutics | January, 04 ,2024 | Unknown | $60,000,000 |
Mozart Therapeutics, Inc | June, 08 ,2023 | Series A | $25,000,000 |
Matter Neuroscience | March, 01 ,2024 | Unknown | $26,000,000 |
Remix Therapeutics | January, 04 ,2024 | Unknown | $60,000,000 |
HI-Bio | January, 05 ,2024 | Series B | $95,000,000 |
Lightcast Discovery | August, 18 ,2023 | Series B | $49,000,000 |
Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
HI-Bio | January, 05 ,2024 | Series B | $95,000,000 |
Moonwalk Biosciences | January, 08 ,2024 | Series A | $57,000,000 |
Generate:Biomedicines | September, 18 ,2023 | Series C | $273,000,000 |
eGenesis, Inc. | September, 04 ,2024 | Series B | $191,000,000 |
Moonwalk Biosciences | January, 08 ,2024 | Series A | $57,000,000 |
Elephas | January, 24 ,2024 | Series C | $55,000,000 |
Magnet Biomedicine | September, 20 ,2023 | Unknown | $50,000,000 |
Accompany Health | February, 01 ,2024 | Series A | $56,000,000 |
Elephas | January, 24 ,2024 | Series C | $55,000,000 |
Basking Biosciences Inc | February, 02 ,2024 | Unknown | $55,000,000 |
AIRNA | September, 20 ,2023 | Unknown | $30,000,000 |
Proniras Corporation | February, 02 ,2024 | Series B | $4,650,000 |
Accompany Health | February, 01 ,2024 | Series A | $56,000,000 |
Matter Neuroscience | March, 01 ,2024 | Unknown | $26,000,000 |
Gate Bioscience | November, 02 ,2023 | Series A | $60,000,000 |
Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
Basking Biosciences Inc | February, 02 ,2024 | Unknown | $55,000,000 |
eGenesis, Inc. | September, 04 ,2024 | Series B | $191,000,000 |
Tome Biosciences | December, 14 ,2023 | Series B | $213,000,000 |
ARCH Venture Partners | September, 04 ,2024 | Series C | Undisclosed Amount |
Proniras Corporation | February, 02 ,2024 | Series B | $4,650,000 |
Rippl | October, 04 ,2024 | Series A | $23,000,000 |
Remix Therapeutics | January, 04 ,2024 | Unknown | $60,000,000 |
Be Biopharma | October, 23 ,2024 | Unknown | $82,000,000 |
Matter Neuroscience | March, 01 ,2024 | Unknown | $26,000,000 |
HI-Bio | January, 05 ,2024 | Series B | $95,000,000 |
Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
Moonwalk Biosciences | January, 08 ,2024 | Series A | $57,000,000 |
eGenesis, Inc. | September, 04 ,2024 | Series B | $191,000,000 |
Elephas | January, 24 ,2024 | Series C | $55,000,000 |
Accompany Health | February, 01 ,2024 | Series A | $56,000,000 |
Basking Biosciences Inc | February, 02 ,2024 | Unknown | $55,000,000 |
Proniras Corporation | February, 02 ,2024 | Series B | $4,650,000 |
Matter Neuroscience | March, 01 ,2024 | Unknown | $26,000,000 |
Mirador Therapeutics | March, 26 ,2024 | Unknown | $400,000,000 |
eGenesis, Inc. | September, 04 ,2024 | Series B | $191,000,000 |
ARCH Venture Partners | September, 04 ,2024 | Series C | Undisclosed Amount |
Rippl | October, 04 ,2024 | Series A | $23,000,000 |
Be Biopharma | October, 23 ,2024 | Unknown | $82,000,000 |
Metsera | November, 14 ,2024 | Series B | $215,000,000 |